The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients

INTRODUCTION: B cell depletion therapy is efficacious in rheumatoid arthritis (RA) patients failing on tumor necrosis factor (TNF) blocking agents. However, approximately 40% to 50% of rituximab (RTX) treated RA patients have a poor response. We investigated whether baseline gene expression levels c...

Descripción completa

Detalles Bibliográficos
Autores principales: Raterman, Hennie G, Vosslamber, Saskia, de Ridder, Sander, Nurmohamed, Michael T, Lems, Willem F, Boers, Maarten, van de Wiel, Mark, Dijkmans, Ben AC, Verweij, Cornelis L, Voskuyl, Alexandre E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446469/
https://www.ncbi.nlm.nih.gov/pubmed/22540992
http://dx.doi.org/10.1186/ar3819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446469/
https://www.ncbi.nlm.nih.gov/pubmed/22540992
http://dx.doi.org/10.1186/ar3819

Ejemplares similares